Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 80 entries
View as:

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase: N/A Priority: Normal
NCT ID: NCT05327530 Org: User:
Start: 08/17/22 End: 07/24/26 Due: 07/24/27

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Phase: N/A Priority: Normal
NCT ID: NCT05464030 Org: User:
Start: 08/04/22 End: 02/27/26 Due: 02/27/27

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

Phase: N/A Priority: Normal
NCT ID: NCT03933215 Org: User:
Start: 05/21/19 End: 03/30/24 Due: 03/30/25

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Phase: N/A Priority: Normal
NCT ID: NCT04170153 Org: User:
Start: 12/20/19 End: 01/30/26 Due: 01/30/27

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04246489 Org: User:
Start: 03/30/20 End: 12/14/22 Due: 12/14/23

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04489940 Org: User:
Start: 10/12/20 End: 07/08/22 Due: 07/08/23

First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

Phase: N/A Priority: Normal
NCT ID: NCT04075721 Org: User:
Start: 09/26/19 End: 04/01/21 Due: 04/01/22

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02278250 Org: User:
Start: 01/26/15 End: 09/24/21 Due: 09/24/22

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03770689 Org: User:
Start: 03/20/19 End: 02/21/22 Due: 02/21/23

Avelumab Program Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT03815643 Org: User:
Start: 03/22/19 End: 02/20/26 Due: 02/20/27

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase: N/A Priority: Normal
NCT ID: NCT02625610 Org: User:
Start: 12/24/15 End: 06/03/21 Due: 06/03/22

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02975349 Org: User:
Start: 03/07/17 End: 04/02/24 Due: 04/02/25

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Phase: N/A Priority: Normal
NCT ID: NCT03306420 Org: User:
Start: 10/03/17 End: 01/14/19 Due: 01/14/20

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Phase: N/A Priority: Normal
NCT ID: NCT03451825 Org: User:
Start: 03/07/18 End: 07/27/21 Due: 07/27/22

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT03833661 Org: User:
Start: 03/26/19 End: 09/30/22 Due: 09/30/23

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase: N/A Priority: Normal
NCT ID: NCT04768296 Org: User:
Start: 03/29/21 End: 07/21/23 Due: 07/21/24

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase: N/A Priority: Normal
NCT ID: NCT02576574 Org: User:
Start: 10/29/15 End: 01/29/24 Due: 01/29/25

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

Phase: N/A Priority: Normal
NCT ID: NCT00436826 Org: User:
Start: 11/30/06 End: 03/31/12 Due: 03/31/13

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06641908 Org: User:
Start: 11/08/24 End: 10/27/27 Due: 10/27/28

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Phase: N/A Priority: Normal
NCT ID: NCT03940703 Org: User:
Start: 09/19/19 End: 10/31/25 Due: 10/31/26

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Phase: N/A Priority: Normal
NCT ID: NCT02395172 Org: User:
Start: 03/24/15 End: 12/03/19 Due: 12/03/20

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Phase: N/A Priority: Normal
NCT ID: NCT06509906 Org: User:
Start: 10/08/24 End: 04/07/26 Due: 04/07/27

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Phase: N/A Priority: Normal
NCT ID: NCT06424717 Org: User:
Start: 08/16/24 End: 01/27/26 Due: 01/27/27

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02644278 Org: User:
Start: 02/29/16 End: 10/19/17 Due: 10/19/18

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Phase: N/A Priority: Normal
NCT ID: NCT06421935 Org: User:
Start: 08/07/24 End: 03/26/26 Due: 03/26/27